UPS Expects FY24 Revenue Of $92B-$94.5B Vs. Consensus Of $95.57B; Sees Consolidated Adjusted Operating Margin Of 10.0%-10.6%.

/ / Industrials /

-8.39% For the full year 2024, UPS expects revenue to range from approximately $92.0 billion to $94.5 billion and consolidated adjusted operating margin to range from approximately 10.0% to 10.6%. The company is planning capital expenditures of about $4.5 billion and dividend payments of around $5.4 billion, subject to board approval. The effective tax rate is expected to be around 23.5%.

UPS Expects FY24 Revenue Of $92B-$94.5B Vs. Consensus Of $95.57B; Sees Consolidated Adjusted Operating Margin Of 10.0%-10.6%. Read Post »

General Motors Releases 2023 Fourth-Quarter and Full-Year Results, and 2024 Guidance

/ / Consumer Discretionary /

GM Releases 2023 Fourth-Quarter and Full-Year Results, and 2024 Guidance PR Newswire DETROIT, Jan. 30, 2024 DETROIT, Jan. 30, 2024 /PRNewswire/ — General Motors Co. (NYSE: GM) today reported fourth-quarter 2023 revenue of $43.0 billion, net income attributable to stockholders of $2.1 billion and EBIT-adjusted of $1.8 billion. GM reported full-year 2023 revenue of $171.8 billion, net income attributable to stockholders of $10.1 billion and EBIT-adjusted of $12.4 billion. The chart below summarizes GM’s 2023 financial guidance and 2023 results, as well as the company’s 2024 guidance, which is for a year of strong financial performance. Final 2023 Guidance 2023 Results 2024 Guidance ——————- ————- ——————- Net income $9.1 billion – $9.7 $10.1 billion $9.8 billion – attributable to billion $11.2 billion stockholders EBIT-adjusted $11.7 billion – $12.4 billion $12.0 billion – $12.7 billion $14.0 billion Automotive operating $19.5 billion – $20.8 billion $18.0 billion – cash flow $21.0 billion

General Motors Releases 2023 Fourth-Quarter and Full-Year Results, and 2024 Guidance Read Post »

Bank of America (NYSE:BAC) Stock Analyst Ratings

/ / Financials /

Bank of America (NYSE:BAC) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 21.16% Morgan Stanley $32 → $41 Upgrades Equal-Weight → Overweight 01/16/2024 0.18% Odeon Capital → $33.9 Downgrades Buy → Hold 01/16/2024 44.8% Oppenheimer $50 → $49 Maintains Outperform 01/16/2024 6.38% BMO Capital $37 → $36 Maintains Market Perform 01/02/2024 27.07% Barclays $39 → $43 Maintains Overweight 12/14/2023 12.12% Odeon Capital → $37.94 Upgrades Hold → Buy 12/01/2023 -2.48% Goldman Sachs $30 → $33 Maintains Buy 11/16/2023 50.71% Oppenheimer $49 → $51 Maintains Outperform 11/06/2023 -11.35% Keefe, Bruyette & Woods $29 → $30 Upgrades Underperform → Market Perform 10/18/2023 44.8% Oppenheimer $48 → $49 Maintains Outperform 10/18/2023 18.2% BMO Capital $39 → $40 Maintains Market Perform 10/03/2023 -5.44% Morgan Stanley $34 → $32 Maintains Equal-Weight 09/26/2023 41.84% Oppenheimer $49 → $48 Maintains Outperform 09/15/2023 -18.74% Piper Sandler $28 → $27.5

Bank of America (NYSE:BAC) Stock Analyst Ratings Read Post »

Wells Fargo (NYSE:WFC) Stock Analyst Ratings

/ / Financials /

Wells Fargo (NYSE:WFC) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 25% Morgan Stanley $54 → $63 Maintains Overweight 01/18/2024 -3.17% Odeon Capital → $48.8 Downgrades Buy → Hold 01/16/2024 -0.79% Piper Sandler $51 → $50 Maintains Neutral 01/16/2024 15.08% Raymond James $55 → $58 Maintains Strong Buy 01/09/2024 1.19% Deutsche Bank → $51 Downgrades Buy → Hold 01/08/2024 9.13% Baird → $55 Downgrades Outperform → Neutral 01/02/2024 30.95% Barclays $54 → $66 Maintains Overweight 12/14/2023 11.27% Odeon Capital → $56.08 Upgrades Hold → Buy 12/08/2023 -6.75% Piper Sandler $45 → $47 Maintains Neutral 12/06/2023 9.13% Raymond James $52 → $55 Maintains Strong Buy 12/04/2023 7.14% Morgan Stanley $52 → $54 Maintains Overweight 12/01/2023 -0.79% Goldman Sachs $45 → $50 Maintains Buy 10/16/2023 7.14% BMO Capital $52 → $54 Maintains Market Perform 09/22/2023 -12.7% Deutsche Bank $44 → $44 Reiterates Buy

Wells Fargo (NYSE:WFC) Stock Analyst Ratings Read Post »

JPMorgan Chase & Co. (NYSE: JPM) Stock Analyst Ratings

/ / Financials /

JPMorgan Chase & Co. (NYSE: JPM) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 28.06% Morgan Stanley $191 → $221 Maintains Overweight 01/16/2024 34.43% Oppenheimer $234 → $232 Maintains Outperform 01/16/2024 15.89% Piper Sandler $190 → $200 Maintains Overweight 01/16/2024 12.41% BMO Capital $192 → $194 Maintains Market Perform 01/09/2024 10.09% Deutsche Bank $140 → $190 Upgrades Hold → Buy 01/04/2024 8.93% B of A Securities $177 → $188 Maintains Buy 01/02/2024 22.84% Barclays $186 → $212 Maintains Overweight 12/18/2023 — Daiwa Capital Upgrades Outperform → Buy 11/16/2023 40.8% Oppenheimer $233 → $243 Maintains Outperform 10/16/2023 -1.49% Piper Sandler $168 → $170 Maintains Overweight 10/16/2023 -0.92% BMO Capital $167 → $171 Maintains Market Perform 10/16/2023 35.01% Oppenheimer $215 → $233 Maintains Outperform 10/16/2023 10.67% Morgan Stanley $187 → $191 Maintains Overweight 10/03/2023 8.36% Morgan Stanley $179 → $187 Maintains Overweight 09/26/2023

JPMorgan Chase & Co. (NYSE: JPM) Stock Analyst Ratings Read Post »

Marathon Petroleum Corp. Reports Fourth-Quarter 2023 Results

/ / Energy /

Marathon Petroleum Corp. Reports Fourth-Quarter 2023 Results PR Newswire FINDLAY, Ohio, Jan. 30, 2024 FINDLAY, Ohio, Jan. 30, 2024 /PRNewswire/ — — Fourth-quarter net income attributable to MPC of $1.5 billion, or $3.84 per diluted share; adjusted net income of $1.5 billion, or $3.98 per adjusted diluted share — Full-year 2023 net income attributable to MPC of $9.7 billion, or $23.63 per diluted share; adjusted net income of $9.7 billion, or $23.63 per adjusted diluted share — Full-year net cash provided by operating activities of $14.1 billion, supporting the return of $12.8 billion of capital to shareholders in 2023 — 2024 MPC standalone (excluding MPLX) capital spending outlook of $1.25 billion Marathon Petroleum Corp. (NYSE: MPC) today reported net income attributable to MPC of $1.5 billion, or $3.84 per diluted share, for the fourth quarter of 2023. This compares to net income attributable to MPC of $3.3 billion, or $7.09

Marathon Petroleum Corp. Reports Fourth-Quarter 2023 Results Read Post »

MSCI Reports Financial Results for Fourth Quarter and Full Year 2023

/ / Financials /

MSCI Reports Financial Results for Fourth Quarter and Full Year 2023 NEW YORK–(BUSINESS WIRE)–January 30, 2024– MSCI Inc. (“MSCI” or the “Company”) (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, today announced its financial results for the three months ended December 31, 2023 (“fourth quarter 2023”) and full year ended December 31, 2023 (“full year 2023”). Financial and Operational Highlights for Fourth Quarter 2023 (Note: Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2022 (“fourth quarter 2022”) and Run Rate percentage changes are relative to December 31, 2022). — Operating revenues of $690.1 million, up 19.8%; Organic operating revenue growth of 14.7% — Recurring subscription revenues up 16.8%; Asset-based fees up 15.9% — Operating margin of 53.7%; Adjusted EBITDA margin of 60.1% — Diluted EPS of $5.07, up 89.9%; Adjusted EPS of $3.68,

MSCI Reports Financial Results for Fourth Quarter and Full Year 2023 Read Post »

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

/ / Health Care /

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance — 2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution — Full-Year 2023 Revenues of $58.5 Billion — Expected Decline in Comirnaty(1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues — Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 7% Operationally, Driven by a Combination of New Product and Indication Launches and In-Line Product Growth — Full-Year 2023 Reported(2) Diluted EPS of $0.37, Down 93% Year-Over-Year, and Adjusted(3) Diluted EPS of $1.84, Down 72% Year-Over-Year, Significantly Impacted by One-Time Events(4) — Fourth-Quarter 2023 Revenues of $14.2 Billion — Expected Decline in Comirnaty(1) and Paxlovid Revenues Drove 42% Operational Decrease in Fourth-Quarter Revenues — Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 8% Operationally —

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance Read Post »

MSCI Expects FY24 Capex of $95M-$105M, Free Cash Flow of $1.225B-$1,285B

/ / Financials /

Full-Year 2024 Guidance MSCI’s guidance for the year ending December 31, 2024 (“Full-Year 2024”) is based on assumptions about a number of factors, in particular related to macroeconomic factors and the capital markets. These assumptions are subject to uncertainty, and actual results for the year could differ materially from our current guidance, including as a result of the uncertainties, risks and assumptions discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form 10-K, as updated in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. See “Forward-Looking Statements” below. Guidance Item Guidance for Full-Year 2024 Operating Expense $1,300 to $1,340 million Adjusted EBITDA Expense $1,130 to $1,160 million Interest Expense (including amortization of financing fees)(1) $185 to $189 million Depreciation & Amortization Expense $170 to $180 million Effective

MSCI Expects FY24 Capex of $95M-$105M, Free Cash Flow of $1.225B-$1,285B Read Post »

Pfizer Q4 Adjusted EPS $0.10 Beats $(0.22) Estimate, Sales $14.25B Beat $14.21B Estimate

/ / Health Care /

Pfizer (NYSE:PFE) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.22) by 145.45 percent. This is a 91.23 percent decrease over earnings of $1.14 per share from the same period last year. The company reported quarterly sales of $14.25 billion which beat the analyst consensus estimate of $14.21 billion by 0.27 percent. This is a 41.34 percent decrease over sales of $24.29 billion the same period last year.

Pfizer Q4 Adjusted EPS $0.10 Beats $(0.22) Estimate, Sales $14.25B Beat $14.21B Estimate Read Post »

Scroll to Top